Trial Profile
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Antineoplastics; Capecitabine; Fluorouracil; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 29 Feb 2024 Planned End Date changed from 25 Jan 2025 to 13 Feb 2025.
- 27 Jan 2024 Planned End Date changed from 31 Dec 2023 to 25 Jan 2025.
- 17 May 2023 Time frame of both the primary endpoints has been changed from 11 years to 14 years.